PFIZER INC Deferred Tax Assets, Equity Method Investments
PFIZER INC (PFE) had Deferred Tax Assets, Equity Method Investments of $234.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsEquityMethodInvestments · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Equity Method Investments $234.00M.
- 2024-12-31: Deferred Tax Assets, Equity Method Investments $73.00M.
- 2023-12-31: Deferred Tax Assets, Equity Method Investments $133.00M.
- 2022-12-31: Deferred Tax Assets, Equity Method Investments $91.00M.
| Period end | Deferred Tax Assets, Equity Method Investments | Deferred Tax Assets, Equity Method Investments as first filed |
|---|---|---|
| 2025-12-31 | $234.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $73.00M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $133.00M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $91.00M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $70.00M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $130.00M 10-K · filed 2022-02-24 | $128.00M 10-K · filed 2021-02-25 |
| 2019-12-31 | $11.00M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $18.00M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |